Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LESLIE BRYAN FORGOSH

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1154305738
CMS profile
278624
Location
SAINT PAUL, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$37.62

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $37.62 2

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Boston Scientific Corporation $22.67 1
Amgen Inc. $14.95 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LESLIE BRYAN FORGOSH

NPI 1154305738 · CMS profile ID 278624

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

SAINT PAUL, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1154305738?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LESLIE BRYAN FORGOSH, NPI 1154305738, CMS profile ID 278624. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1154305738?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). LESLIE BRYAN FORGOSH, NPI 1154305738, CMS profile ID 278624. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1154305738?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
LESLIE BRYAN FORGOSH, NPI 1154305738, CMS profile ID 278624, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1154305738?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $37.62 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boston Scientific Corporation $22.6712/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662643119 CMS
Amgen Inc. $14.9502/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662637654 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $37.62 2
PY2020 $13.55 1
PY2022 $3,264.08 18
PY2023 $2,534.72 16
PY2024 $1,618.47 10
PY2025 $1,013.54 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,031.09 11
PY2025 Principal investigator $1,145,528.44 27
PY2024 Principal investigator $1,362,432.04 31
PY2023 Recipient $140.82 1
PY2023 Principal investigator $1,104,464.55 33
PY2022 Recipient $3,197.00 1
PY2022 Principal investigator $739,768.96 53
PY2021 Recipient $4,441.01 1
PY2021 Principal investigator $667,326.41 59
PY2020 Recipient $6,717.97 2
PY2020 Principal investigator $475,435.63 71
PY2019 Principal investigator $661,892.22 89

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

73 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Amgen Inc. $29,820.00 12/24/2020 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
FOURIER OLE (Ph 4) No dispute reported 06/30/2026 753887881
Recipient Eli Lilly and Company $5,444.00 12/22/2020 Covered Recipient Physician THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 728721057
Principal investigator 1 Kowa Research Institute, Inc. $6,489.00 12/22/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 721659163
Principal investigator 1 SANOFI US SERVICES INC. $3,532.00 12/21/2020 Non-covered Recipient Entity
Healtheast Medical Research Institu
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk No dispute reported 06/30/2026 744051165
Principal investigator 1 Esperion Therapeutics, Inc. $637.00 12/18/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737200915
Principal investigator 1 Esperion Therapeutics, Inc. $252.00 12/18/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737200919
Principal investigator 1 Kowa Research Institute, Inc. $8,807.40 12/17/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 721659157
Principal investigator 1 Amgen Inc. $4,740.80 12/02/2020 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
VESALIUS - CV No dispute reported 06/30/2026 753889161
Principal investigator 1 Kowa Research Institute, Inc. $5,221.80 12/01/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 721659151
Principal investigator 1 Amgen Inc. $24,068.40 11/23/2020 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
FOURIER OLE (Ph 4) No dispute reported 06/30/2026 753887665
Principal investigator 1 SANOFI US SERVICES INC. $3,332.00 11/23/2020 Non-covered Recipient Entity
Healtheast Medical Research Institu
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk No dispute reported 06/30/2026 744051150
Principal investigator 1 Esperion Therapeutics, Inc. $359.00 11/16/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737198607
Principal investigator 1 Esperion Therapeutics, Inc. $252.00 11/16/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737198609
Principal investigator 1 Esperion Therapeutics, Inc. $252.00 11/16/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737198615
Principal investigator 1 Esperion Therapeutics, Inc. $252.00 11/16/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737198621
Principal investigator 1 Amgen Inc. $2,370.40 11/11/2020 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
VESALIUS - CV No dispute reported 06/30/2026 753888947
Principal investigator 1 Kowa Research Institute, Inc. $4,023.00 11/03/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 721659147
Principal investigator 1 Esperion Therapeutics, Inc. $252.00 11/02/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737197659
Principal investigator 1 Amgen Inc. $1,185.20 10/30/2020 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
VESALIUS - CV No dispute reported 06/30/2026 753888867
Principal investigator 1 SANOFI US SERVICES INC. $4,794.00 10/26/2020 Non-covered Recipient Entity
Healtheast Medical Research Institu
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk No dispute reported 06/30/2026 744051101
Principal investigator 1 Amgen Inc. $1,185.20 10/19/2020 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
VESALIUS - CV No dispute reported 06/30/2026 753888811
Principal investigator 1 Amgen Inc. $1,185.20 10/15/2020 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
VESALIUS - CV No dispute reported 06/30/2026 753888785
Principal investigator 1 Amryt Pharma Holdings Ltd $1,000.00 10/07/2020 Non-covered Recipient Entity
Health East Medical Research Institute
LOWER: Lomitapide Observational Worldwide Evaluation Registry No dispute reported 06/30/2026 721461447
Principal investigator 1 Amryt Pharma Holdings Ltd $2,500.00 10/07/2020 Non-covered Recipient Entity
Health East Medical Research Institute
LOWER: Lomitapide Observational Worldwide Evaluation Registry No dispute reported 06/30/2026 721461449
Principal investigator 1 Kowa Research Institute, Inc. $500.00 10/01/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 721659141
Principal investigator 1 AKEBIA THERAPEUTICS INC $500.00 09/25/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753286463
Principal investigator 1 Esperion Therapeutics, Inc. $637.00 09/24/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737194043
Principal investigator 1 Esperion Therapeutics, Inc. $32.40 09/24/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737194045
Principal investigator 1 AKEBIA THERAPEUTICS INC $500.00 09/23/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753286443
Principal investigator 1 AKEBIA THERAPEUTICS INC $6,005.00 09/23/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753286447
Principal investigator 1 Kowa Research Institute, Inc. $5,070.60 09/23/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 721659117
Principal investigator 1 SANOFI US SERVICES INC. $3,349.00 09/02/2020 Non-covered Recipient Entity
Healtheast Medical Research Institu
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk No dispute reported 06/30/2026 744051133
Principal investigator 1 Kowa Research Institute, Inc. $3,740.40 08/26/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 721659123
Principal investigator 1 Kowa Research Institute, Inc. $2,484.00 08/18/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 721659129
Recipient Eli Lilly and Company $1,273.97 08/14/2020 Covered Recipient Physician THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 728724483
Principal investigator 1 SANOFI US SERVICES INC. $1,215.00 08/04/2020 Non-covered Recipient Entity
Healtheast Medical Research Institu
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk No dispute reported 06/30/2026 744051115
Principal investigator 1 Kowa Research Institute, Inc. $2,808.00 07/27/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 721659135
Principal investigator 1 Amgen Inc. $598.00 07/23/2020 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
VESALIUS - CV No dispute reported 06/30/2026 731644949
Principal investigator 1 AKEBIA THERAPEUTICS INC $418.05 07/13/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753285649
Principal investigator 1 AKEBIA THERAPEUTICS INC $2,819.10 07/01/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753285197
Principal investigator 1 SANOFI US SERVICES INC. $1,348.00 06/22/2020 Non-covered Recipient Entity
Healtheast Medical Research Institu
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk No dispute reported 06/30/2026 744051047
Principal investigator 1 SANOFI US SERVICES INC. $1,756.00 06/08/2020 Non-covered Recipient Entity
Healtheast Medical Research Institu
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk No dispute reported 06/30/2026 744051039
Principal investigator 1 AKEBIA THERAPEUTICS INC $298.80 06/02/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753284245
Principal investigator 1 Kowa Research Institute, Inc. $1,562.40 06/01/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 721659113
Principal investigator 1 Kowa Research Institute, Inc. $1,589.40 05/15/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 721659109
Principal investigator 1 AKEBIA THERAPEUTICS INC $216.00 05/12/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753283793
Principal investigator 1 AKEBIA THERAPEUTICS INC $216.00 05/06/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753283563
Principal investigator 1 Kowa Research Institute, Inc. $2,059.20 04/24/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 721659103
Principal investigator 1 SANOFI US SERVICES INC. $3,918.00 04/20/2020 Non-covered Recipient Entity
Healtheast Medical Research Institu
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk No dispute reported 06/30/2026 744051033
Principal investigator 1 Merck Sharp & Dohme Corporation $2,500.00 04/06/2020 Covered Recipient Teaching Hospital
HEALTHEAST ST JOSEPHS HOSPITAL
A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejection fraction HFrEF - VerICiguaT glObal study in subjects with heart failure and Reduced ejectIon frAction VICTORIA No dispute reported 06/30/2026 740818419
Principal investigator 1 AKEBIA THERAPEUTICS INC $793.80 04/01/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753282639
Principal investigator 1 Kowa Research Institute, Inc. $8,060.40 04/01/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 721659101
Principal investigator 1 Amgen Inc. $10,696.00 03/21/2020 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
VESALIUS - CV No dispute reported 06/30/2026 731644953
Principal investigator 1 Amgen Inc. $5,585.00 03/20/2020 Covered Recipient Teaching Hospital
HEALTHEAST ST JOSEPHS HOSPITAL
FOURIER OLE (Ph 4) No dispute reported 06/30/2026 731649093
Principal investigator 1 SANOFI US SERVICES INC. $2,634.00 03/03/2020 Non-covered Recipient Entity
Healtheast Medical Research Institu
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk No dispute reported 06/30/2026 744051025
Principal investigator 1 AKEBIA THERAPEUTICS INC $637.20 02/25/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753289319
Principal investigator 1 Kowa Research Institute, Inc. $7,165.80 02/19/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 721659097
Principal investigator 1 AKEBIA THERAPEUTICS INC $637.20 02/11/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753288775
Principal investigator 1 SANOFI US SERVICES INC. $500.00 02/10/2020 Non-covered Recipient Entity
Healtheast Medical Research Institu
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk No dispute reported 06/30/2026 744050999
Principal investigator 1 SANOFI US SERVICES INC. $2,015.00 02/10/2020 Non-covered Recipient Entity
Healtheast Medical Research Institu
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk No dispute reported 06/30/2026 744051005
Principal investigator 1 SANOFI US SERVICES INC. $3,448.00 02/04/2020 Non-covered Recipient Entity
Healtheast Medical Research Institu
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk No dispute reported 06/30/2026 744050991
Principal investigator 1 Amgen Inc. $16,415.00 01/30/2020 Covered Recipient Teaching Hospital
HEALTHEAST ST JOSEPHS HOSPITAL
FOURIER OLE (Ph 4) No dispute reported 06/30/2026 731649089
Principal investigator 1 Amryt Pharma Holdings Ltd $590.80 01/29/2020 Non-covered Recipient Entity
HealthEast Medical Research Institute
LOWER: Lomitapide Observational Worldwide Evaluation Registry No dispute reported 06/30/2026 721461269
Principal investigator 1 AstraZeneca Pharmaceuticals LP $51,405.50 01/28/2020 Non-covered Recipient Entity
Healtheast Medical Research Institute
An International, Double-blind, Randomised, Placebo-Controlled Phase IIIb Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF) No dispute reported 06/30/2026 736735905
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,274.40 01/27/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753288121
Principal investigator 1 Kowa Research Institute, Inc. $1,564.20 01/21/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 721659093
Principal investigator 1 Amgen Inc. $11,637.08 01/15/2020 Non-covered Recipient Entity
HEALTHEAST MEDICAL RESEARCH INSTITUTE
VESALIUS - CV No dispute reported 06/30/2026 731644957
Principal investigator 1 Amgen Inc. $166,636.80 01/10/2020 Covered Recipient Teaching Hospital
HEALTHEAST ST JOSEPHS HOSPITAL
FOURIER OLE (Ph 4) No dispute reported 06/30/2026 731649097
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,000.00 01/10/2020 Non-covered Recipient Entity
HEALTH EAST OSTEOPOROSIS CARE
A MULTICENTER RANDOMIZED DOUBLE BLIND PARALLEL GROUP ACTIVE CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LCZ696 COMPARED TO VALSARTAN ON MORBIDITY AND MORTALITY IN HEART FAILURE PATIENTS NYHA CLASS II TO IV WITH PRESERVED EJECTION FRACTION No dispute reported 06/30/2026 721492051
Principal investigator 1 AKEBIA THERAPEUTICS INC $500.00 01/02/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753286277
Principal investigator 1 AKEBIA THERAPEUTICS INC $723.60 01/02/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753287603
Principal investigator 1 Kowa Research Institute, Inc. $3,376.80 01/02/2020 Non-covered Recipient Entity
HEALTH EAST MEDICAL RESEARCH INSTITUTE
K-877-302 No dispute reported 06/30/2026 721659089
Principal investigator 1 Novartis Pharmaceuticals Corporation $24,488.30 01/02/2020 Non-covered Recipient Entity
FAIRVIEW HEALTH SERVICES CLCZ696D2301
AN OPEN-LABEL EXTENSION TRIAL OF THE PHASE III LIPID-LOWERING TRIALS TO ASSESS THE EFFECT OF LONG TERM DOSING OF INCLISIRAN GIVEN AS SUBCUTANEOUS INJECTIONS IN SUBJECTS WITH HIGH CARDIOVASCULAR RISK AND ELEVATED LDL-C No dispute reported 06/30/2026 965470843